Document Detail


Efficacy of a continuous estrogen-progestin regimen in the menopausal patient.
MedLine Citation:
PMID:  3574823     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The major concern with the use of unopposed estrogen is its neoplastic effect on the endometrium. Progestins used to oppose the estrogen may be associated with vaginal bleeding and reversal of estrogen's protective changes in serum lipoprotein concentrations. A study was performed in which all postmenopausal women received conjugated equine estrogen for days 1-28; with group I receiving 2.5 mg medroxyprogesterone acetate for days 1-28, group II receiving 5 mg medroxyprogesterone acetate for days 1-28, and group III receiving 5 mg medroxyprogesterone acetate for days 17-28. Pre- and postdrug evaluations of the endometrium revealed atrophic changes after therapy with continuous combined estrogen-progestin. Pre- and poststudy evaluation of serum lipoprotein concentrations demonstrated significant declines in cholesterol and low-density lipoprotein cholesterol within groups I and III, and no change in group II. All patients kept a weekly diary recording any vaginal bleeding or change in vasomotor symptoms. The results suggest that a continuous regimen of 0.625 mg conjugated equine estrogen with 2.5 mg medroxyprogesterone acetate is beneficial as a primary hormonal replacement therapy for the postmenopausal patient.
Authors:
L Weinstein
Related Documents :
15132723 - Dose-, igf-i- and sex-dependent changes in lipid profile and body composition during gh...
9920073 - Growth hormone replacement therapy in the elderly with hypothalamic-pituitary disease: ...
8673823 - A community trial of ivermectin for onchocerciasis in sierra leone: compliance and para...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Obstetrics and gynecology     Volume:  69     ISSN:  0029-7844     ISO Abbreviation:  Obstet Gynecol     Publication Date:  1987 Jun 
Date Detail:
Created Date:  1987-06-19     Completed Date:  1987-06-19     Revised Date:  2009-10-26    
Medline Journal Info:
Nlm Unique ID:  0401101     Medline TA:  Obstet Gynecol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  929-32     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Climacteric / drug effects
Drug Therapy, Combination
Endometrium / drug effects
Estrogens / administration & dosage*
Female
Humans
Lipoproteins / blood
Medroxyprogesterone / administration & dosage*
Menopause*
Middle Aged
Random Allocation
Chemical
Reg. No./Substance:
0/Estrogens; 0/Lipoproteins; 520-85-4/Medroxyprogesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An evaluation of late luteal phase endometrium in women requesting reversal of tubal ligation.
Next Document:  Resumption of ovulation after ectopic pregnancy.